118 related articles for article (PubMed ID: 32814663)
1. Time to achieve a prostate-specific antigen nadir of ≤0.2 ng/mL and related factors after permanent prostate brachytherapy.
Soyano T; Yorozu A; Natsume N; Hanada T; Shiraishi Y; Toya K; Saito S
Brachytherapy; 2021; 20(1):29-37. PubMed ID: 32814663
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
[TBL] [Abstract][Full Text] [Related]
5. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
6. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
[TBL] [Abstract][Full Text] [Related]
7. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
8. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
9. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M
Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170
[TBL] [Abstract][Full Text] [Related]
10. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
11. Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer.
Critz FA
J Urol; 2002 Dec; 168(6):2434-8. PubMed ID: 12441934
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
Critz FA; Levinson AK; Williams WH; Holladay DA
J Clin Oncol; 1996 Nov; 14(11):2893-900. PubMed ID: 8918485
[TBL] [Abstract][Full Text] [Related]
13. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
[TBL] [Abstract][Full Text] [Related]
15. Comparison of biochemical failure definitions for permanent prostate brachytherapy.
Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Zelefsky MJ; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1487-93. PubMed ID: 16750326
[TBL] [Abstract][Full Text] [Related]
16. A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure.
Taussky D; Bedwani S; Meissner N; Bahary JP; Lambert C; Barkati M; Beauchemin MC; Ménard C; Delouya G
Brachytherapy; 2018; 17(2):277-282. PubMed ID: 29306674
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
18. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]